All In Biotech

Drug Trial Radar · NCT02451137

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)

A Randomized, Open-label, Parallel Group Real World Pragmatic Trial to Assess the Clinical and Health Outcomes of Toujeo Compared to Commercially Available Basal Insulins for Initiation of Therapy in Insulin-naive Patients With Uncontrolled Type 2 Diabetes Mellitus

Last checked: Nov 20, 2026Latest source record: Sep 10, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 3,304 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,304

Actual

Start

Jun 16, 2015

Primary completion

Mar 2, 2018

Study completion Aug 9, 2018

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
May 21, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: Demonstrate clinical benefit of Toujeo in achieving individualized Healthcare Effectiveness Data and Information Set (HEDIS) glycated hemoglobin (HbA1c) targets (\<8% if age \>=65 years or with defined comorbidities or otherwise \<7%) at 6 months without documented symptomatic (Blood Glucose \<=70 mg/deciliter \[mg/dL\]) and/or severe hypoglycemia at any time of day from baseline to 6 months in uncontrolled insulin naive participants with type 2 diabetes initiating basal insulin therapy in a real world setting. Secondary Objectives: Compare Toujeo to other commercially available basal insulins at 6 months after initiating insulin therapy in a real world setting in terms of: * Participant persistence with assigned basal insulin therapy. * Risk of hypoglycemia including the incidence and rate of documented symptomatic and severe hypoglycemia. * Changes in HbA1c, fasting plasma glucose, body weight * Differences in participant and provider- reported outcomes (including Diabetes Treatment Satisfaction Questionnaire Status and Change Versions (DTSQs) and (DTSQc), Hypoglycemia Patient Questionnaire, and participant and provider reported Global Effectiveness Scale (GES). * Healthcare resource utilization including hospitalizations and emergency department or other provider visits and healthcare costs.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • Insulin glargine, 300 U/mlDrug

    Pharmaceutical form: solution Route of administration: subcutaneous

  • Insulin glargine, 100 U/mlDrug

    Pharmaceutical form: solution Route of administration: subcutaneous

  • Insulin detemirDrug

    Pharmaceutical form: solution Route of administration: subcutaneous

  • Background TherapyDrug

    Anti-diabetic drugs at investigator discretion and consistent with local labeling guidelines for use with insulin.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Individualized Glycated Hemoglobin Target Attainment Per Healthcare Effectiveness Data and Information Set (HEDIS) Criteria Without Documented Symptomatic(Blood Glucose <=70 mg/dL [<=3.9 mmol/L]) and/or Severe HypoglycemiaTime frame: Baseline to Month 6

Locations

427 sites in 2 countries. Site status is shown where the registry gives one.

  • Investigational Site Number 840731

    Birmingham, Alabama

  • Investigational Site Number 840305

    Birmingham, Alabama

  • Investigational Site Number 840811

    Birmingham, Alabama

  • Investigational Site Number 840218

    Gulf Shores, Alabama

  • Investigational Site Number 840739

    Guntersville, Alabama

  • Investigational Site Number 840367

    Huntsville, Alabama

  • Investigational Site Number 840130

    Montgomery, Alabama

  • Investigational Site Number 840729

    Montgomery, Alabama

  • Investigational Site Number 840281

    Saraland, Alabama

  • Investigational Site Number 840613

    Sheffield, Alabama

  • Investigational Site Number 840634

    Sheffield, Alabama

  • Investigational Site Number 840654

    Sheffield, Alabama

  • Investigational Site Number 840173

    Phoenix, Arizona

  • Investigational Site Number 840555

    Phoenix, Arizona

  • Investigational Site Number 840805

    Sun City, Arizona

  • Investigational Site Number 840725

    Conway, Arkansas

  • Investigational Site Number 840790

    Jonesboro, Arkansas

  • Investigational Site Number 840699

    Little Rock, Arkansas

  • Investigational Site Number 840528

    Little Rock, Arkansas

  • Investigational Site Number 840079

    Searcy, Arkansas

  • Investigational Site Number 840337

    Bakersfield, California

  • Investigational Site Number 840089

    El Cajon, California

  • Investigational Site Number 840024

    Escondido, California

  • Investigational Site Number 840020

    Fresno, California

  • Investigational Site Number 840470

    Imperial, California

  • Investigational Site Number 840155

    Inglewood, California

  • Investigational Site Number 840161

    Inglewood, California

  • Investigational Site Number 840194

    Laguna Hills, California

  • Investigational Site Number 840710

    Laguna Hills, California

  • Investigational Site Number 840204

    Lancaster, California

  • Investigational Site Number 840371

    Los Angeles, California

  • Investigational Site Number 840310

    Los Angeles, California

  • Investigational Site Number 840504

    Los Angeles, California

  • Investigational Site Number 840340

    Los Angeles, California

  • Investigational Site Number 840309

    Los Gatos, California

  • Investigational Site Number 840256

    North Hollywood, California

  • Investigational Site Number 840015

    Northridge, California

  • Investigational Site Number 840056

    Norwalk, California

  • Investigational Site Number 840090

    Orange, California

  • Investigational Site Number 840078

    Palm Springs, California

Showing 40 of 427 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.